Purpose: To assess and compare demographic and clinical features of benign and malignant eyelid tumors from 2011 to 2018 in a tertiary medical center.

Materials And Methods: The study was conducted retrospectively from medical records to compare demographic and clinical characteristics and recurrence of benign and malignant eyelid tumors after obtaining institutional review board approval. A total of 428 eyelid tumors with histopathologic diagnoses were studied. Premalignant lesions were not included. The lesions were classified into two groups according to malignancy: benign and malignant eyelid lesions.

Results: Among the 428 histopathologically confirmed eyelid lesions, 373 (87.1%) were benign and 55 (12.9%) were malignant. The patients with malignant eyelid tumors had a higher mean age at diagnosis than patients with benign eyelid tumors (P=0.012). The most common benign eyelid tumors were squamous papilloma (17.7%), xanthelasma (11.5%), and epidermal cysts (11.3%). The most common malignant eyelid tumors were basal cell carcinomas (65.5%), squamous cell carcinomas (14.5%), and sebaceous gland carcinomas (7.3%). There was no relative gender predominance between patients with benign and malignant eyelid tumors (P=0.287). Benign eyelid tumors were most commonly located on the right side and upper eyelid (P=0.027 and 0.036, respectively). Malignant tumors had a higher rate of recurrence (P=0.002).

Conclusion: Differentiation between benign and malignant eyelid lesions is important, since it may lead to cosmetic complications and serious morbidity, particularly in patients with malignant eyelid tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfo.2020.07.019DOI Listing

Publication Analysis

Top Keywords

eyelid tumors
44
malignant eyelid
36
benign malignant
24
eyelid
15
tumors
12
benign eyelid
12
malignant
11
benign
10
compare demographic
8
demographic clinical
8

Similar Publications

Article Synopsis
  • Primary cutaneous mucinous carcinoma (PCMC) is a rare skin cancer that primarily develops from eccrine sweat glands, commonly appearing on the head and neck of older adults and often exhibiting slow growth.
  • Although it rarely spreads to other parts of the body, PCMC has a high rate of recurrence, making early and accurate diagnosis through biopsy crucial.
  • A case study of a 77-year-old man highlighted the challenges in diagnosing PCMC, leading to surgical removal and further treatment, ultimately resulting in no signs of recurrence one year later.
View Article and Find Full Text PDF

Facial lymphedema (FL) is a potential complication following head-and-neck tumor (HNT) therapy. Conservative management is often difficult, and there is limited literature on surgical treatments for FL. This report presents three cases of FL treated with lymphaticovenular anastomosis (LVA).

View Article and Find Full Text PDF

Objective: To study the prevalence, clinical presentation, treatment, and follow-up of ocular (dermal) melanocytosis (ODM) and its association with choroidal melanoma (CM) in Asian Indian patients.

Methods: This was a retrospective case series of patients with ODM conducted in a quaternary eye care center.

Results: Of the total 1.

View Article and Find Full Text PDF

AI-driven eyelid tumor classification in ocular oncology using proteomic data.

NPJ Precis Oncol

December 2024

Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Eyelid tumors pose diagnostic challenges due to their diverse pathological types and limited biopsy materials. This study aimed to develop an artificial intelligence (AI) diagnostic system for accurate classification of eyelid tumors. Utilizing mass spectrometry-based proteomics, we analyzed proteomic data from eight tissue types and identified eighteen novel biomarkers based on 233 formalin-fixed, paraffin-embedded (FFPE) samples from 150 patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!